Cost‐Effectiveness of Ivabradine for Heart Failure in the United States

BACKGROUND: Ivabradine is a heart rate–lowering agent approved to reduce the risk of hospitalization for worsening heart failure. This study assessed the cost‐effectiveness of adding ivabradine to background therapy in the United States from the perspective of a commercial or Medicare Advantage paye...

Descripción completa

Detalles Bibliográficos
Autores principales: Kansal, Anuraag R., Cowie, Martin R., Kielhorn, Adrian, Krotneva, Stanimira, Tafazzoli, Ali, Zheng, Ying, Yurgin, Nicole
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4889192/
https://www.ncbi.nlm.nih.gov/pubmed/27153871
http://dx.doi.org/10.1161/JAHA.116.003221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4889192/
https://www.ncbi.nlm.nih.gov/pubmed/27153871
http://dx.doi.org/10.1161/JAHA.116.003221

Ejemplares similares